The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $8...

Sanofi and Regeneron’s Libtayo is on a roll with its second FDA nod in just two weeks. And the latest green light breaks the PD-1 inhibitor out of its skin cancer co...

Novo Nordisk’s Ozempic is already ducking it out with Eli Lilly’s Trulicity in the once-weekly diabetes treatment field. But looming competition from the Indianapoli...

Johnson & Johnson has been battling for years against lawsuits claiming its talc powders cause cancer, but now investors are getting a sense of what the litigati...